Researchers have unveiled the structure of a unique amyloid beta protein associated with Alzheimer's progression. This protein forms small aggregates that disrupt brain function. Importantly, the study found that lecanemab, a recently FDA-approved Alzheimer's treatment, can neutralize these disruptive aggregates, hinting at its potential to slow down the disease's cognitive decline.
